Cargando…

UGT1A1 genetic variants are associated with increases in bilirubin levels in rheumatoid arthritis patients treated with sarilumab

Sarilumab is a human monoclonal antibody against interleukin (IL)-6Rα that has been approved for the treatment of adult patients with moderately to severely active rheumatoid arthritis (RA) and an inadequate response or intolerance to one or more disease-modifying antirheumatic drugs (DMARDs). Mild...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lin, Nan, Damask, Amy, Boyapati, Anita, Hamilton, Jennifer D., Hamon, Sara, Ternes, Nils, Nivens, Michael C., Penn, John, Lopez, Alexander, Reid, Jeffrey G., Overton, John, Shuldiner, Alan R., Abecasis, Goncalo, Baras, Aris, Paulding, Charles
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9151390/ https://www.ncbi.nlm.nih.gov/pubmed/35149777 http://dx.doi.org/10.1038/s41397-022-00269-5

Ejemplares similares

Population Pharmacodynamic Model of Neutrophil Margination and Tolerance to Describe Effect of Sarilumab on Absolute Neutrophil Count in Patients with Rheumatoid Arthritis
por: Kovalenko, Pavel, et al.
Publicado: (2020)

UGT1A1-related Bilirubin Encephalopathy/Kernicterus in Adults
por: Bai, Jie, et al.
Publicado: (2021)

UGT1A1 is a major locus influencing bilirubin levels in African Americans
por: Chen, Guanjie, et al.
Publicado: (2012)

Efficacy and Safety of Sarilumab in Hospitalized Patients With Coronavirus Disease 2019: A Randomized Clinical Trial
por: Sivapalasingam, Sumathi, et al.
Publicado: (2022)

UGT1A1 sequence variants and bilirubin levels in early postnatal life: a quantitative approach
por: Hanchard, Neil A, et al.
Publicado: (2011)

Neobavaisoflavone Induces Bilirubin Metabolizing Enzyme UGT1A1 via PPARα and PPARγ
por: Zhu, Ya-Di, et al.
Publicado: (2021)

Serum Bilirubin Levels and Promoter Variations in HMOX1 and UGT1A1 Genes in Patients with Fabry Disease
por: Jirásková, Alena, et al.
Publicado: (2017)

Epidemiology of DYT1 dystonia: Estimating prevalence via genetic ascertainment
por: Park, Joseph, et al.
Publicado: (2019)

UGT1A1 promoter polymorphism associated with serum bilirubin level in Saudi patients with sickle cell disease
por: Hamad, Zainab, et al.
Publicado: (2013)

Influence of UGT1A1 Genetic Variants on Free Bilirubin Levels in Japanese Newborns: A Preliminary Study
por: Hanafusa, Hiroaki, et al.
Publicado: (2022)

Sarilumab monotherapy vs sarilumab and methotrexate combination therapy in patients with rheumatoid arthritis
por: Burmester, Gerd R, et al.
Publicado: (2021)

Serum Bilirubin Concentration in Healthy Adult North-Europeans Is Strictly Controlled by the UGT1A1 TA-Repeat Variants
por: Kringen, Marianne K., et al.
Publicado: (2014)

UGT1A1 mutation association with increased bilirubin levels and severity of unconjugated hyperbilirubinemia in ABO incompatible newborns of China
por: Yang, Hui, et al.
Publicado: (2021)

Sarilumab plus methotrexate suppresses circulating biomarkers of bone resorption and synovial damage in patients with rheumatoid arthritis and inadequate response to methotrexate: a biomarker study of MOBILITY
por: Boyapati, Anita, et al.
Publicado: (2016)

Impairment of enzymatic antioxidant defenses is associated with bilirubin-induced neuronal cell death in the cerebellum of Ugt1 KO mice
por: Bortolussi, G, et al.
Publicado: (2015)

Bilirubin Links HO-1 and UGT1A1*28 Gene Polymorphisms to Predict Cardiovascular Outcome in Patients Receiving Maintenance Hemodialysis
por: Ho, Yang, et al.
Publicado: (2021)

Body Fat Percentage Is a Major Determinant of Total Bilirubin Independently of UGT1A1*28 Polymorphism in Young Obese
por: Belo, Luís, et al.
Publicado: (2014)

A UGT1A1 variant is associated with serum total bilirubin levels, which are causal for hypertension in African-ancestry individuals
por: Chen, Guanjie, et al.
Publicado: (2021)

Pharmacokinetics and Pharmacodynamics of Subcutaneous Sarilumab and Intravenous Tocilizumab Following Single‐Dose Administration in Patients With Active Rheumatoid Arthritis on Stable Methotrexate
por: Paccaly, Anne J., et al.
Publicado: (2020)

Sarilumab and adalimumab differential effects on bone remodelling and cardiovascular risk biomarkers, and predictions of treatment outcomes
por: Gabay, Cem, et al.
Publicado: (2020)

High levels of interleukin-6 in patients with rheumatoid arthritis are associated with greater improvements in health-related quality of life for sarilumab compared with adalimumab
por: Strand, Vibeke, et al.
Publicado: (2020)

Serum bilirubin concentration is modified by UGT1A1 Haplotypes and influences risk of Type-2 diabetes in the Norfolk Island genetic isolate
por: Benton, M. C., et al.
Publicado: (2015)

Activation of Alternative Bilirubin Clearance Pathways Partially Reduces Hyperbilirubinemia in a Mouse Model Lacking Functional Ugt1a1 Activity
por: Banerjee, Bhaswati, et al.
Publicado: (2022)

Differences in UGT1A1, UGT1A7, and UGT1A9 Polymorphisms between Uzbek and Japanese Populations
por: Maeda, Hiromichi, et al.
Publicado: (2014)

Sarilumab: Cytomegalovirus colitis: case report
Publicado: (2020)

Identification of sarilumab pharmacodynamic and predictive markers in patients with inadequate response to TNF inhibition: a biomarker substudy of the phase 3 TARGET study
por: Gabay, Cem, et al.
Publicado: (2018)

Association of Low Serum Bilirubin Concentrations and Promoter Variations in the UGT1A1 and HMOX1 Genes with Type 2 Diabetes Mellitus in the Czech Population
por: Jirásková, Alena, et al.
Publicado: (2023)

A phase 3 randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of sarilumab in patients with giant cell arteritis
por: Schmidt, Wolfgang A., et al.
Publicado: (2023)

Exome-Wide Association Study Identifies New Low-Frequency and Rare UGT1A1 Coding Variants and UGT1A6 Coding Variants Influencing Serum Bilirubin in Elderly Subjects: A Strobe Compliant Article
por: Oussalah, Abderrahim, et al.
Publicado: (2015)

Profiling of UGT1A1(*)6, UGT1A1(*)60, UGT1A1(*)93, and UGT1A1(*)28 Polymorphisms in Indonesian Neonates With Hyperbilirubinemia Using Multiplex PCR Sequencing
por: Amandito, Radhian, et al.
Publicado: (2019)

Subcutaneous Sarilumab in Patients With Rheumatoid Arthritis who Previously Received Subcutaneous Sarilumab or Intravenous Tocilizumab: An Open‐Label Extension of a Randomized Clinical Trial
por: Emery, Paul, et al.
Publicado: (2020)

Commentary: Profiling of UGT1A1(*)6, UGT1A1(*)60, UGT1A1(*)93, and UGT1A1(*)28 Polymorphisms in Indonesian Neonates With Hyperbilirubinemia Using Multiplex PCR Sequencing
por: Heydari, Mohammad Reza, et al.
Publicado: (2020)

Polymorphisms of UGT1A1(*)6, UGT1A1(*)27 & UGT1A1(*)28 in three major ethnic groups from Malaysia
por: Teh, L. K., et al.
Publicado: (2012)

Genome‐wide association analysis of serum alanine and aspartate aminotransferase, and the modifying effects of BMI in 388k European individuals
por: Gao, Chuan, et al.
Publicado: (2021)

UGT1A1(∗)28 relationship with abnormal total bilirubin levels in chronic hepatitis C patients: Outcomes from a case–control study
por: de Souza, Marcelo Moreira Tavares, et al.
Publicado: (2017)

Genotyping of UGT1A1*80 as an Alternative to UGT1A1*28 Genotyping in Spain
por: Bravo-Gómez, Adrián, et al.
Publicado: (2022)

Sarilumab: patient-reported outcomes in rheumatoid arthritis
por: Crotti, Chiara, et al.
Publicado: (2018)

Population Pharmacokinetics of Sarilumab in Patients with Rheumatoid Arthritis
por: Xu, Christine, et al.
Publicado: (2019)

Sarilumab: Perforated duodenal ulcer: case report
Publicado: (2021)

Long-term safety and efficacy of sarilumab plus methotrexate on disease activity, physical function and radiographic progression: 5 years of sarilumab plus methotrexate treatment
por: Genovese, Mark C, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_los5e8ck04n25q89ivvsrej60o